ORIGINAL ARTICLE. Key words benign prostatic hyperplasia, bother, lower urinary tract symptoms, quality of life, tamsulosin
|
|
- Ezra Pearson
- 5 years ago
- Views:
Transcription
1 LUTS (2012) 4, ORIGINAL ARTICLE Correlations among Lower Urinary Tract Symptoms, Bother, and Quality of Life in Patients with Benign Prostatic Hyperplasia and Associated Fluctuations with Tamsulosin Administration Momokazu GOTOH, 1 Yoshihisa MATSUKAWA, 1 Yasuhito FUNAHASHI, 1 Masashi KATO, 1 Yoshiro MASEKI, 2 Harunori NARITA, 3 Osamu KAMIHIRA, 4 and Ryohei HATTORI 1 1 Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2 Department of Urology, Maseki Clinic, Nagoya, Japan, 3 Department of Urology, Narita Clinic, Nagoya, Japan, and 4 Department of Urology, Komaki Municipal Hospital, Komaki, Japan Objectives: To estimate correlations among lower urinary tract symptoms (LUTS), bother, and quality of life (QOL) and assess fluctuations in these parameters after α1-blocker administration in patients with benign prostatic hyperplasia (BPH). Methods: Untreated BPH patients with international prostate symptom scores (IPSS) 8 and IPSS-QOL scores 2 were administered tamsulosin at 0.2 mg/day for 4 weeks in a prospective multicenter study. We subsequently estimated the IPSS, bother score for each IPSS item, BPH impact index (BII), and IPSS-QOL score before and 4 weeks after tamsulosin administration. We also analyzed the LUTS that might strongly influence QOL by using a path analysis model. Results: Analyzable data were obtained from 198 of the 257 patients enrolled. The IPSS were highest for LUTS such as slow stream, followed by increased daytime frequency and nocturia. The bother score was highest for slow stream, followed by nocturia. We observed dissociations between IPSS and bother scores for both urgency and nocturia. After tamsulosin administration, total and individual IPSS, total and individual bother scores, total and individual BII scores, and IPSS-QOL score demonstrated significant improvements. Path analysis showed that physical discomfort and bothersomeness were BII items that strongly influenced QOL. Furthermore, feeling of incomplete, urgency, and slow stream were LUTS that strongly influenced QOL. Conclusion: Tamsulosin administration improved patient QOL by possible mechanisms via improvement in subjective symptoms and bother. The LUTS that strongly influenced QOL comprised feeling of incomplete, urgency, and slow stream. Key words benign prostatic hyperplasia, bother, lower urinary tract symptoms, quality of life, tamsulosin 1. INTRODUCTION Recent epidemiological studies conducted in many countries have demonstrated that a large number of people have lower urinary tract symptoms (LUTS) and that LUTS negatively impact the quality of life (QOL) in a variety of domains of daily life. 1 4 Awareness of the great demand for treating LUTS has promoted active development of various therapeutic modalities, including a variety of new medicines. Bother and QOL assessment of patients with LUTS has recently been suggested as an important factor for selecting an appropriate treatment strategy, in addition to LUTS assessment itself. 5 8 Nonetheless, correlations among three factors, namely, patient LUTS, bother, and QOL, and fluctuations in these factors affected by treatment have not been adequately estimated. This study investigated correlations among LUTS, bother, and QOL, as well as fluctuations in these factors following α1-blocker administration. 2. METHODS The study protocol was evaluated and approved by the ethics committee at Nagoya University Graduate School of Medicine prior to initiation. All patients provided written informed consent prior to their enrollment in the study. This was a prospective, open-labeled, multicenter study. Previously untreated benign prostatic hyperplasia (BPH) patients with international prostate symptom scores (IPSS) 8, IPSS-QOL scores 2, and prostate volume >20 ml Correspondence: Momokazu Gotoh, MD, PhD, Department of Urology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya , Japan. Tel: ; Fax: gotoh@med.nagoya-u.ac.jp Received 26 August 2011; revised 12 October 2011; accepted 24 October DOI: /j x
2 46 Momokazu Gotoh et al. TABLE 1. Changes of the international prostate symptom scores (IPSS), bother score and benign prostatic hyperplasia impact index after tamsulosin treatment Variable Before treatment After treatment P-value IPSS (n = 198) 2.4 ± 1.8 (2: 1 4) 1.6 ± 1.4 (1: 0.8 2) < Daytime frequency 3.0 ± 1.5 (3: 2 4) 1.9 ± 1.4 (2: 1 3) < ± 1.9 (2: 1 4) 1.6 ± 1.5 (1: 0 2.3) < ± 1.7 (1: 0 3) 1.0 ± 1.2 (1: 0 1.3) < ± 1.6 (4: 3 5) 2.2 ± 1.6 (2: 1 3) < ± 1.7 (1.5: 0 3) 1.3 ± 1.4 (1: 0 2) < ± 1.3 (2: 1 3) 1.8 ± 1.1 (2: 1 2) < IPSS total score 17.7 ± 6.3 (16: 12 22) 11.3 ± 6.1 (10: 6 16) < Voiding score 7.9 ± 3.8 (8: 5 11) 5.0 ± 3.7 (4: 2 7) < Storage score 7.4 ± 3.2 (7: 5 10) 4.7 ± 2.5 (4: 3 6) < QOL index 4.7 ± 0.9 (5: 4 6) 3.2 ± 1.5 (3: 2 4) < Bother score (n = 198) 2.5 ± 1.1 (3: 2 3) 1.9 ± 1.1 (2: 1 3) < Daytime frequency 2.6 ± 1.0 (3: 2 3) 2.0 ± 1.1 (2: 1 3) < ± 1.1 (3: 2 3) 1.8 ± 1.1 (2: 1 3) < ± 1.1 (2: 2 3) 1.7 ± 1.1 (1: 1 2) < ± 0.8 (3: 3 4) 2.0 ± 1.0 (2: 1 3) < ± 1.1 (2: 1 3) 1.6 ± 1.0 (2: 1 2) < ± 1.0 (3: 2 4) 2.3 ± 1.1 (2: 1 3) < BII (n = 166) discomfort 1.9 ± 0.9 (2: 1 3) 1.2 ± 0.8 (1: 1 2) < ± 1.0 (2: 1 2) 1.2 ± 0.9 (1: 1 2) < ± 0.9 (2: 1 3) 1.2 ± 0.9 (1: 1 2) < Time kept from usual activities 1.1 ± 1.2 (1: 0 2) 0.6 ± 0.9 (0: 0 1) < BII total 6.8 ± 3.8 (7: 4 9) 4.2 ± 3.2 (4: 2 6) < Data presented as mean ± standard deviation (median: 25 75th percentile) *Wilcoxon s signed-ranks test. BII, benign prostatic hyperplasia impact index; QOL, quality of life. were administered tamsulosin at 0.2 mg/day for 4 weeks, which was the standard dose approved in Japan. Prostate volume was measured by transabdominal ultrasonography. Exclusion criteria were as follows: (i) concomitant other lower urinary tract disorders such as prostate cancer, bladder tumor, bladder calculus, prostatitis, urethral structure, etc.; (ii) active urinary tract infection; (iii) neurogenic bladder; (iv) serious cardiac depression, cardiovascular accident, hepatic dysfunction, or renal dysfunction; (v) hypersensitivity to tamsulosin; and (vi) use of a therapeutic agent that affects lower urinary tract function within 1 week of starting tamsulosin treatment in this study. Concomitant use of the following agents that might affect lower urinary tract function were prohibited: hormonal agents, α- orβ-adrenoceptor antagonists, anticholinergics, cholinergic agonists, and antidepressants. At baseline and after a 4-week administration of tamsulosin, subjective symptoms, patients bother from the symptoms, and impact of symptoms on patients QOL were assessed by self-administered questionnaires. Subjective symptoms were assessed using IPSS, and QOL was evaluated using IPSS-QOL and BPH impact index (BII). 9 Japanese versions of IPSS, IPSS-QOL, and BII had been psychometrically validated. 10 Patients bother was assessed by a face-scale questionnaire based on IPSS; each item of IPSS was rated from 0 to 4 using a face scale (Appendix). The questionnaire was conceived to measure patients bother corresponding to each symptom included in IPSS, although not psychometrically validated. The score data for questionnaires were presented as means (standard deviation [SD]) (median: 25 75th percentile) (Table 1). The changes in scores between baseline and post-administration of tamsulosin were analyzed using a stratified Wilcoxon s signed-rank test. All tests were two-sided, and P-values less than 0.05 were considered statistically significant. In addition to the assessment of subjective symptoms, bother, and QOL, a path analysis was conducted to explore the key symptoms that affect QOL. The outline of the model is illustrated in Figure 1. In the path analysis, after bother and BII scores were determined for each item of IPSS and IPSS-QOL before and after a 4-week treatment with tamsulosin hydrochloride, an analysis was performed using a structural equation model (SEM) 11,12 based on the following assumptions and with adjustment for background factors such as prostate volume (as its objective finding) and medical history: (i) the frequency of each symptom has a direct effect on bother of the corresponding symptom; (ii) bother of each symptom has a direct effect on the four BII items; (iii) the QOL score is directly affected by the four BII items; and (iv) the baseline severity of each symptom has a direct effect on the post-treatment severity of the corresponding subjective symptom. It was assumed that there is error correlation among the four BII items, although the details are omitted. Estimation was made via the maximum likelihood method using Amos 7.0 (IBM Corporation, Armonk, NY, USA). To test model fit, we used goodness-of-fit index, and calculated the appropriate sample size based
3 Correlation among LUTS, Bother, and QOL 47 Before Treatment After Treatment QOL BPH Impact Index Time kept from Usual Activities Bother score IPSS Symptom IPSS Symptom Bother score BPH Impact Index Time kept from Usual Activities QOL Fig. 1 Outline of the model. In the path analysis, an analysis was performed using a structural equation model after bother and benign prostatic hyperplasia (BPH) impact index scores were determined for each item of international prostate symptom scores (IPSS) and IPSS-quality of life (QOL) score before and after treatment. The paths between observed variables were set as follows: boxes represent observed variables; and arrows represent direct effects (correlations among error variables and among explanatory variables are not illustrated in this figure). on this goodness-of-fit index. The sample size to get the appropriate value of RMSA (Root Mean Square Error of Approximation) <0.08 was calculated to be 157 patients. 3. RESULTS Fifty-nine patients were excluded from the initial group of 257, and the remaining 198 patients were included in the analysis. Reasons for exclusion were as follows: 21 patients did not have a second visit after tamsulosin administration; 15 did not satisfy the selection criteria; 6 patients did not satisfy the medication period; 7 patients had prohibited concomitant drugs; 6 discontinued tamsulosin because of adverse events; and 4 patients lacked data on their questionnaires. Mean age of the analyzed patients was 68.3 years (SD: 8.6; median: 70; 25 75th percentile: 63 73), and mean prostate volume was 33.6 ml (SD: 33.6; median: 31.1; 25 75th percentile: ). The scores for each item in IPSS and IPSS bother questionnaire at baseline and after tamsulosin treatment are shown in Table 1. The evaluation of pretreatment IPSS yielded the highest score for slow stream, followed by increased daytime frequency. LUTS with the highest bother score was for slow stream, followed by nocturia. For slow stream, both IPSS and bother scores were highest. Dissociations were observed between IPSS and bother scores in both urgency and nocturia. The score of each item in BII is listed in Table 1. Although high scores were observed in items of physical discomfort and bothersomeness, the score in time kept from usual activities was lower than for other items. After tamsulosin treatment, mean total IPSS significantly decreased from 17.7 to Scores of all items of IPSS and IPSS bother score also demonstrated significant decreases (Table 1). BII total score, IPSS-QOL score, and scores of all items of BII demonstrated significant decreases (Table 1). For 163 patients with all data available, path analysis was performed to determine LUTS that may affect QOL. For all symptoms, the regression coefficient of frequency on the bother score was significant and positive both before and after treatment, indicating a natural tendency that higher frequency of subjective symptoms was associated with greater bother. The goodness-of-fit indices are shown in Table 2. The standardized regression coefficients of bother on QOL are shown in Figure 2. Both before and after treatment, physical discomfort and bothersomeness were TABLE 2. Goodness-of-fit indices CFI RMSEA Chi-squared Degrees of freedom AIC Model The CFI of model are around 0.87, which is just under the desirable value 0.9, but this value is considered to be acceptable because the RMSEAs are under AIC, akaike s information criterion; CFI, comparative fit index; RMSEA, root mean square error of approximation.
4 48 Momokazu Gotoh et al. (a) I- I-PSS Bother score score BII Daytime Frequency * * * * * * ** QOL Index * Time kept from Usual Activities (b) I- I-PSS Bother Bother score score BII BII Daytime Frequency * * * * * * ** * * ** * * ** * * * QOL Index * * * Time kept from Usual Activities Fig. 2 Path diagram. The standardized regression coefficients of bother (international prostate symptom scores [IPSS] bother score) and quality of life (QOL) (benign prostatic hyperplasia impact index [BII], IPSS-QOL index) are shown in the path diagram for (a) pre- and (b) post-treatment. discomfort, bothersomeness and worry about of BII items have a significant effect on QOL index after treatment. According to the standardized regression coefficient of bother on BII, feeling of incomplete, urgency and slow stream significantly affect the BII items. P < 0.05, P < influential on the QOL score. In addition to physical discomfort and bothersomeness, worry about had a significant effect after treatment, showing that the BII items that affected QOL were physical discomfort, worry about, and bothersomeness. The R 2 value was lower at baseline (0.24) than after treatment (0.4). This may have been because subjects were screened with a certain level of IPSS at baseline (cut-off effect). As for the standardized regression coefficient of bother on BII, feeling of incomplete, urgency, and slow stream significantly affected the BII items. In addition, the effect of nocturia on bothersomeness could not be ignored, although not significant at a level of 5% (P = 6%). At baseline, feeling of incomplete significantly affected physical discomfort and bothersomeness, both of which were most influential on IPSS. Consequently, three LUTS, namely, feeling of incomplete
5 Correlation among LUTS, Bother, and QOL 49, urgency, and slow stream, were found to affect QOL. 4. DISCUSSION Assessment of symptom and bother at baseline demonstrated that slow stream was associated with high IPSS and bother scores. In contrast, dissociation between IPSS and bother scores was observed in nocturia and urgency. This is consistent with the report by Yoshida et al. that slow stream and nocturia were frequent symptoms (IPSS), and that dissociation between IPSS and bother scores was observed in nocturia and urgency. 13 For nocturia and urgency associated with the dissociation between IPSS and bother scores, it may be necessary to assess not only the frequency of symptoms (IPSS) but also the degree of distress, such as the bother score, to make an adequate decision in selecting treatment options and evaluating therapeutic efficacy. After treatment with tamsulosin, total and individual IPSS, total and individual bother scores, total and individual BII scores, and IPSS-QOL score were significantly improved (Table 1). Even for nocturia and urgency associated with the dissociation between IPSS and bother scores, both scores were significantly improved, suggesting that tamsulosin improved not only the frequency of symptoms but also the degree of distress, which contributed to improvement in QOL. In the present study, treatment efficacy was measured after a rather short administration period of 4 weeks, which might be open to criticism. However, it has recently been well known that α1-blocker works as quickly as a few days and its efficacy is evident by 4 weeks. The path analysis revealed that three BII items physical discomfort, worry about, and bothersomeness affected QOL after treatment. The remaining BII item, time kept from usual activities, which posed no problem in BPH patients with low scores at baseline, did not significantly affect QOL. BII items like physical discomfort, worry about, and bothersomeness were affected by the bother score for feeling of incomplete, urgency, and slow stream. Although it has been commonly reported that urgency and slow stream negatively affect patients QOL, 14,15 few studies have investigated the impact of feeling of incomplete voiding on QOL. The symptom of feeling of incomplete voiding used to be included in the voiding symptoms; however, this symptom was regarded as a post-micturition symptom, which was newly categorized in the new terminology on lower urinary tract function reported by the International Continence Society in Interestingly, the BII score was closely correlated with post-micturition symptoms, storage symptoms, and voiding symptoms, which are three subgroups of LUTS. These findings suggest that feeling of incomplete voiding, the newly categorized postmicturition symptom, needs to be further investigated for its impact on bother and QOL of patients. In contrast, intermittency was negatively correlated with the BII item of bothersomeness. This may have been because the effect of improvement in other symptoms was greater than that in intermittency, rather than improvement in intermittency reducing the QOL. At baseline, the path analysis showed that QOL was affected by two BII items, namely, physical discomfort and bothersomeness, which in turn were affected by the bother score for feeling of incomplete. The degree of freedom adjusted R 2, which represents the goodness-of-fit indices was lower at baseline than after treatment. This may be explained by the cut-off effect resulting from screening of subjects with an IPSS of 8 and an IPSS-QOL score of 2. In the present study, BII score-based path analysis did not identify nocturia as a factor affecting QOL. However, there have been many reports that nocturia exerts a negative impact on QOL in a variety of domains of daily life. 17,18 BII did not include susceptible domains that were affected by the presence of nocturia; this might be the reason that nocturia did not show a strong correlation to QOL in the present study. -specific questionnaires such as nocturia quality of life, rather than BII, should therefore have been used to evaluate the effect of nocturia on QOL. In conclusion, the BII-score path analysis revealed that the LUTS affecting QOL were feeling of incomplete, urgency, and slow stream, which were typical post-micturition, storage, and voiding symptoms, respectively. Tamsulosin improved the three voiding, storage, and post-micturition symptoms in a balanced manner, thereby leading to improvement in BII and QOL. In the assessment of QOL in patients with diseases such as BPH, it may be important to assess not only the frequency of symptoms but also the degree of distress from a multilateral perspective, that is, to assess the patient-reported outcomes Disclosure There are no financial or commercial interests for the authors of the present paper. REFERENCES 1. Irwin DE, Milsom I, Hunsker S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE, Wagner TH. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care 2009; 15: S Robert G, Descazeaud A, Azzouzi R et al. Impact of lower urinary tract symptoms on discomfort in men aged between 50and80years. Urol Int 2010; 84: Coyne KS, Wein AJ, Tubaro A et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on -related quality of life, anxiety and depression: Epi- LUTS. BJU Int 2009; 103: Marschall-Kehrel D, Roberts RG, Brubaker L. Patientreported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology 2006; 68:
6 50 Momokazu Gotoh et al. 6. Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on -related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 2006; 68: Montorsi F, Henkel T, Geboers A et al. Effect of dutastride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-tosevere benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract 2010; 64: Kaplan SA, Roehrborn CG, Chapple CR et al. Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. BJU Int 2009; 103(Suppl 3): Barry MJ, Fowler FJ, O Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association. Med Care 1995; 33: AS Homma Y, Tsukamoto T, Yasuda K, Ozono S, Yoshida M, Yamaguchi T. Evaluation of psychometric properties of Japanese version of international prostate symptom score and BPH impact index. Nippon Hinyoukika Gakkai Zasshi 2003; 94: Bollen KA. Structural Equations with Latent Variables. New York: John Wiley & Sons, Bollen KA. Latent variables in psychology and the social sciences. Annu Rev Psychol 2002; 53: Yoshida M, Sugiyama Y, Masunaga K et al. Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score. Drugs Today 2007; 43(Suppl B): Sand PK, Steers WD, Dmochowski R, Andoh M, Forero- Schwanhaeuser S. Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20: Marklund-Bau H, Edell-Gustafsson U, Spangberg A. Bothersome urinary symptoms and disease-specific quality of life in patients with benign prostatic obstruction. Scand J Urol Nephrol 2007; 41: Abrams P, Cardozo L, Fall M et al. The standardization of terminology in lower urinary tract function: report from the Standardization Subcommittee of the International Continence Society. Urology 2003; 61: Chartier-Kastler E, Leger D, Montauban V, Comet D, Haab F. Impact of nocturia on sleep efficacy in patients with benign prostatic hypertrophy. Prog Urol 2009; 19: van Dijk MM, Wijkstra H, Debruyne FM, de la Rosette JJ, Michel MC. The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU Int 2010; 105: APPENDIX Bother score IF you have a urinary symptom, how would you rate how much it bothers you? Please make a mark on the scale below the corresponding face for each urinary symptom. 0: Delighted 1: Mostly satisfied 2: Mixed: About equally satisfied and dissatisfied 3: Mostly dissatisfied 4: Terrible How often have you had a sensation of not your bladder completely after you finished urination? How often have you had to urinate again less two hours after finished urinating? How often have you found you stopped and started again several times when you urinated? How often have you found it difficult to postpone urination? How often have you had a weak urinary stream? How often have you had a push or strain to begin urination? How many times did you most typically get up to urinate from the time you went to bed at night until the time you get up in the morning?
The patient, your co-pilot in assessing LUTS
The patient, your co-pilot in assessing LUTS Frank Van der Aa Leuven, Belgium This symposium is supported by Astellas Pharma Europe Ltd., including speaker honoraria and production of materials the slides
More information50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms?
PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS What is Benign Prostatic Hyperplasia (enlarged prostate)? Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate, the gland that
More informationEfficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study
Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study Yoshihisa Matsukawa,* Momokazu Gotoh, Tomonori Komatsu, Yasuhito Funahashi, Naoto Sassa and Ryohei Hattori
More informationSilodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial
The study protocol was approved by the ethics committee and institutional review board of Nihon University School of Medicine. Written informed consent was obtained from all patients. From December 2007
More informationEffects of Melatonin and Rilmazafone on Nocturia in the Elderly
The Journal of International Medical Research 2007; 35: 685 691 Effects of Melatonin and Rilmazafone on Nocturia in the Elderly K SUGAYA, S NISHIJIMA, M MIYAZATO, K KADEKAWA AND Y OGAWA Division of Urology,
More informationKey words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin.
The Professional Medical Journal DOI: 10.17957/TPMJ/17.4102 ORIGINAL PROF-4102 PROSTATIC HYPERPLASIA; COMPARISON BETWEEN TAMSULOSIN AND TERAZOSIN FOR EFFICACY IN MEDICAL MANAGEMENT OF LOWER URINARY TRACT
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationINJINTERNATIONAL. Original Article INTRODUCTION
Official Journal of Korean Continence Society / Korean Society of Urological Research / The Korean Children s Continence and Enuresis Society / The Korean Association of Urogenital Tract Infection and
More informationImpact of smoking on Lower Urinary Tract Symptoms (LUTS) - Single tertiary centre experience
International Journal of Scientific and Research Publications, Volume 6, Issue 5, May 2016 119 Impact of smoking on Lower Urinary Tract Symptoms (LUTS) - Single tertiary centre experience AUB Pethiyagoda
More informationThe Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence
european urology supplements 5 (2006) 849 853 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence Stefano
More informationOriginal Article. Introduction. Methods. Abstract
Blackwell Science, LtdOxford, UKIJUInternational Journal of Urology0919-81722003 Blackwell Publishing Asia Pty LtdNovember 20031011587594Original ArticleUsefulness of a1-blockers in BPHI Ikemoto et al.
More informationCitation The Journal of urology (2010), 184( Right Research, Inc. Published by Elsevie
Title Efficacy of nondrug lifestyle measu nocturia. Author(s) Soda, Takeshi; Masui, Kimihiko; Oku Ogawa, Osamu; Yoshimura, Koji Citation The Journal of urology (2010), 184( Issue Date 2010-09 URL http://hdl.handle.net/2433/129437
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationAssociation of BPH with OAB: The Plumbing or the Pump?
Association of BPH with OAB: The Plumbing or the Pump? Ryan P. Terlecki, MD FACS Associate Professor of Urology Director, Men s Health Clinic Director, GURS Fellowship in Reconstructive Urology, Prosthetic
More informationEfficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study
LUTS () 3, 36 4 ORIGINAL ARTICLE Efficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study Naoki WADA, Masaki WATANABE, Masafumi
More informationINVESTIGATION OF LOWER URINARY TRACT SYMPTOMS IN UROLOGICAL OUTPATIENTS USING ORIGINAL IPSS PLUS POST MICTURITION DRIBBLE QUESTIONNAIRE
INVESTIGATION OF LOWER URINARY TRACT SYMPTOMS IN UROLOGICAL OUTPATIENTS USING ORIGINAL IPSS PLUS POST MICTURITION DRIBBLE QUESTIONNAIRE Tadashi Hanail*, Seiji Matsumotol*, Nobutaka Shimizu, Hirotsugu Uemural
More informationTzu Chi Medical Journal
Tzu Chi Medical Journal 25 (2013) 98e102 Contents lists available at SciVerse ScienceDirect Tzu Chi Medical Journal journal homepage: www.tzuchimedjnl.com Original Article First-line antimuscarinic monotherapy
More informationWho Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign Prostatic Hyperplasia?
LUTS (2013) 5, 145 149 ORIGINAL ARTICLE Who Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign rostatic Hyperplasia? Jun OBATA, Kazuhiro
More informationRELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
American Urological Association symptom index for BPH RELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, AND DISEASE-SPECIFIC QUALITY OF LIFE QUESTION IN PATIENTS WITH
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationOriginal Article. J Fac Med Baghdad 119. Nibbras I. AL-Hamdani* Ali W. Zeki*** Introduction:
Original Article The Efficacy of Solifenacin Added to Α-Adrenergic Antagonists in the Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia (The Iraqi Experience) Nibbras
More informationRole of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label, pilot study
European Review for Medical and Pharmacological Sciences 2017; 21: 4941-4945 Role of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label,
More informationShrestha A, Chalise PR, Sharma UK, Gyawali PR, Shrestha GK, Joshi BR. Department of Surgery, TU Teaching Hospital, Maharajgunj, Kathmandu, Nepal
Original Article Intravesical Prostatic Protrusion is better than Prostate Volume in Predicting Symptom Severity in Benign Prostatic Hyperplasia: A Prospective Clinical Study Shrestha A, Chalise PR, Sharma
More informationBJUI. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction
21 THE AUTHORS; 21 Lower Urinary Tract WORLDWIDE PREVALENCE OF LUTS IRWIN ET AL. BJUI Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder
More informationTitle of Research Thesis:
Eastern Michigan University By Fatai Osinowo Adviser s Name: Dr. Stephen Sonstein, PhD Title of Research Thesis: A sub-analyses from the Benign Prostatic Hyperplasia (BPH) Registry and Patient survey:
More informationL ower urinary tract symptoms (LUTS) are a major health problem and are prevalent in men aged.45 years1 3.
OPEN SUBJECT AREAS: UROGENITAL DISEASES DRUG DEVELOPMENT Received 23 October 2013 Accepted 15 January 2014 Published 4 February 2014 Correspondence and requests for materials should be addressed to P.H.
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationα 1 adrenergic receptor antagonists versus placebo for female lower urinary tract symptoms: A meta analysis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 10: 251-256, 2015 α 1 adrenergic receptor antagonists versus placebo for female lower urinary tract symptoms: A meta analysis PENG ZHANG 1, WAN LI HU 1, BEI CHENG
More informationThe impact of overactive bladder on quality of life in south of China
The impact of overactive bladder on quality of life in south of China Dong Chen, Yining Li * Department of Urology, Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China. * Corresponding
More informationEmployers in the United States have become more cognizant
n report n Impact of Overactive Bladder on Work Productivity in the United States: Results From EpiLUTS Chris C. Sexton, PhD; Karin S. Coyne, PhD, MPH; Vasudha Vats, MPH; Zoe S. Kopp, PhD, MPH; Debra E.
More informationEffect of Transurethral Resection of the Prostate Based on the Degree of Obstruction Seen in Urodynamic Study
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.12.840 Voiding Dysfunction/Female Urology Effect of Transurethral Resection of the Prostate Based on the Degree of Obstruction Seen in Urodynamic
More informationComparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder
European Urology European Urology 48 (2005) 110 115 Female UrologyöIncontinence Comparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder Martin
More informationISSN: (Print) (Online) Journal homepage:
Archives of Andrology Journal of Reproductive Systems ISSN: 0148-5016 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/iaan19 CHANGE IN INTERNATIONAL PROSTATE SYMPTOM SCORE AFTER TRANSURETHRAL
More information(2) Assistant Professor of Pathology
The Association between (Serum prostatic specific antigen and Dihydrotestosterone) and Efficacy of Solifenacin Therapy for Benign prostatic hypertrophy Patient in Salahalddin (1) Mohammed Mohsin Abdul-Aziz,
More informationManagement of LUTS. Simon Woodhams February 2012
Management of LUTS Simon Woodhams February 2012 The management of lower urinary tract symptoms (LUTS) in men Implementing NICE guidance May 2010 NICE clinical guideline 97 Background Lower urinary tract
More informationAlpha antagonists from initial concept to routine clinical practice
european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice
More informationPrevalence, Severity, and Symptom Bother of Lower Urinary Tract Symptoms among Men in the EPIC Study: Impact of Overactive Bladder
EUROPEAN UROLOGY 56 (2009) 14 20 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Voiding Dysfunction Editorial by Christopher R. Chapple on pp. 21 23 of this
More informationUvA-DARE (Digital Academic Repository)
UvA-DARE (Digital Academic Repository) Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional
More informationAnticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female
More informationSeasonal Variation of Urinary Symptoms in Korean Men with Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2015 August 33(2): 81-87 http://dx.doi.org/10.5534/wjmh.2015.33.2.81 Original Article Seasonal Variation of Urinary Symptoms in Korean Men with Lower
More informationAriana L. Smith and Alan J. Wein Division of Urology, Hospital of University of Pennsylvania, Philadelphia, PA, USA
; 2011 Mini Reviews PHARMACOLOGICAL MANAGEMENT OF NOCTURIA SMITH and WEIN BJUI Outcomes of pharmacological management of with non-antidiuretic agents: does statistically significant equal clinically significant?
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationComparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
LUTS (2017) 9, 176 186 ORIGINAL ARTICLE Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia Masaki YOSHIDA, 1, Hideki ORIGASA,
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page 1377-1386 Evaluation of Silodosin in Comparison to Tamuslosin in Treatment of Benign Prostatic Hyperplasia with lower Urinary
More informationImpact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile Function
www.kjurology.org DOI:10.4111/kju.2011.52.1.49 Sexual Dysfunction Impact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile
More informationIntroduction. EAPEN RS, RADOMSKI SB. Gender differences in overactive bladder. Can J Urol 2016;23(Suppl 1):2-9.
Renu S. Eapen, MD, Sidney B. Radomski, MD Division of Urology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada EAPEN RS, RADOMSKI SB. Gender differences in overactive bladder.
More informationA SURVEY ON LOWER URINARY TRACT SYMPTOMS (LUTS) AMONG PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH) IN HOSPITAL UNIVERSITI SAINS MALAYSIA (HUSM)
Malaysian Journal of Medical Sciences, Vol. 14, No. 2, July 2007 (67-71) SHORT COMMUNICATION A SURVEY ON LOWER URINARY TRACT SYMPTOMS (LUTS) AMONG PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH) IN HOSPITAL
More informationEUROPEAN UROLOGY 63 (2013)
EUROPEAN UROLOGY 63 (2013) 158 165 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Voiding Dysfunction Editorial by Christian Gratzke and Karl-Erik Andersson
More informationEVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT
Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor
More informationPRABHAKAR SINGH*, MANOJ INDURKAR, AMITA SINGH, PALLAVI INDURKAR
Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 5, Issue 1, 2013 Research Article COMPARISON OF THE EFFICACY AND SAFETY OF TAMSULOSIN (0.4 V/S (and) FINASTERIDE
More informationOveractive Bladder beyond antimuscarinics
Overactive Bladder beyond antimuscarinics Marcus Drake Bristol Urological Institute Conflicts of interest; Allergan, AMS, Astellas, Ferring, Pfizer Getting the diagnosis right Improving treatment Improving
More informationBJUI. Validity and reliability of the patient s perception of intensity of urgency scale in overactive bladder
; 2010 Lower Urinary Tract PATIENT S PERCEPTION OF INTENSITY OF URGENCY SCALE IN OAB CARTWRIGHT ET AL. BJUI Validity and reliability of the patient s perception of intensity of urgency scale in overactive
More informationVoiding Dysfunction. Jae Hyun Bae, Sun Ouck Kim 1, Eun Sang Yoo 2, Kyung Hyun Moon 3, Yoon Soo Kyung 4, Hyung Jee Kim 4
www.kjurology.org DOI:10.4111/kju.2011.52.4.274 Voiding Dysfunction Efficacy and Safety of Low-Dose Propiverine in Patients with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia with Storage Symptoms:
More informationCooled ThermoTherapy TM
Are BPH Medications Weighing You Down? Think Outside the Pillbox Cooled ThermoTherapy TM A non-surgical, 30 minute in-office treatment that provides long-term relief from BPH symptoms and urinary obstruction
More informationA Comparison of the Frequencies of Medical Therapies for Overactive Bladder in Men and Women: Analysis of More Than 7.2 Million Aging Patients
EUROPEAN UROLOGY 57 (2010) 586 591 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Voiding Dysfunction Editorial by Roger Dmochowski on pp. 592 593 of this
More informationBPH: a present and future perspective on health impact
BPH: a present and future perspective on health impact Burden of disease in men with moderate LUTS Dalibor Pacík This presentation is financially supported by GlaxoSmithKline. CZ/DUTT/0019/12 Men with
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationCorrespondence should be addressed to Yoshinori Tanaka;
Hindawi Advances in Urology Volume 2017, Article ID 4842025, 6 pages https://doi.org/10.1155/2017/4842025 Clinical Study The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment
More informationThe Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
More informationAdditional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy
Original Article - Female Urology Investig Clin Urol Posted online 217.6.27 Posted online 217.6.27 pissn 2466-493 eissn 2466-54X Additional low-dose antimuscarinics can improve overactive bladder symptoms
More informationNew Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital
New Treatment Modalities for Benign Prostatic Hyperplasia Seung-June Oh, MD Department of Urology, Seoul National University Hospital Options for Treating BPH Pharmacotherapy blocker Agents for BPH + OAB
More informationThe prevalence of lower urinary tract symptoms in population aged 40 years or over, in South Korea
Original Article - Lower Urinary Tract Dysfunction pissn 2466-493 eissn 2466-4X The prevalence of lower urinary tract symptoms in population aged 4 years or over, in South Korea Tag Keun Yoo 1, Kyu-Sung
More informationHEALTH AND WELLBEING IMPACT AND TREATMENT OF NOCTURIA A REVIEW OF THE LITERATURE
HEALTH AND WELLBEING IMPACT AND TREATMENT OF NOCTURIA A REVIEW OF THE LITERATURE Nadir I. Osman, 1 Christopher Hillary, 1 *Christopher R. Chapple 2 1. Clinical Research Fellow, Department of Urology, Royal
More informationReliability and Validity of the Persian Language Version of the Female Lower Urinary Tract Symptoms Long form Questionnaire
Original Article Reliability and Validity of the Persian Language Version of the Female Lower Urinary Tract Symptoms Long form Questionnaire Abstract Background: Lower urinary tract symptoms (LUTS) are
More informationLONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
0022-5347/03/1702-0498/0 Vol. 170, 498 502, August 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000076140.68657.fd LONG-TERM SAFETY
More informationLUTS in the modern era. Dr Jon Rees Tyntesfield Medical Group
LUTS in the modern era Dr Jon Rees Tyntesfield Medical Group In the past! Man with urinary symptoms = PROSTATISM Prostatism = TURP TURP unsuccessful = REDO TURP Redo TURP unsuccessful = can t help you!
More informationEAU GUIDELINES POCKET EDITION 3
EAU GUIDELINES POCKET EDITION 3 CONTENTS: BENIGN PROSTATIC HYPERPLASIA URINARY INCONTINENCE UROLITHIASIS 2 3 EAU POCKET GUIDELINES POCKET EDITION 3 This is one of a series of convenient pocket size books
More informationOveractive bladder (OAB) syndrome is a collection
n report n The Total Economic Burden of Overactive Bladder in the United States: A Disease-Specific Approach Ebere Onukwugha, PhD; Ilene H. Zuckerman, PharmD, PhD; Diane McNally, BSPharm, MS; Karin S.
More informationPatient Expectations Following Greenlight XPS
Patient Expectations Following Greenlight XPS 1. Hematuria it is common for men to have light pink to cherry red urine following the procedure. This small amount of blood in the urine usually resolves
More informationMale LUTS, OAB, Sex: natural history. JR Sathiya
Male LUTS, OAB, Sex: natural history JR Sathiya Definitions Newer concepts of LUTs Natural history of BPH Prevalence of LUTs Definition BPH- represents a histologic diagnosis that refers to the proliferation
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme Clinical guideline CG97: The management of lower urinary tract symptoms in men Publication date May
More informationUrinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
More informationAs man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder LUTS 2. Prevalence of BPH LUTS 5
BPH / LUTS Dr Jonny Coxon MA MD MRCS MRCGP DRCOG Beaconsfield Medical Practice, Brighton As man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder
More informationINTERNATIONAL PROSTATE SYMPTOM SCORE IPSS - AUA AS DISCRIMINAT SCALE IN 400 MALE PATIENTS WITH LOWER URINARY TRACT SYMPTOMS (LUTS)
Urological Neurology International Braz J Urol Official Journal of the Brazilian Society of Urology IPSS IN MALE PATIENTS WITH LUTS Vol. 30 (2): 135-141, March - April, 2004 INTERNATIONAL PROSTATE SYMPTOM
More informationStrong Impact of Nocturia on Sleep Quality in Patients with Lower Urinary Tract Symptoms
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2012 August 30(2): 123-130 http://dx.doi.org/10.5534/wjmh.2012.30.2.123 Original Article Strong Impact of Nocturia on Sleep Quality in Patients with
More informationIranian Version of Overactive Bladder Symptom Scale: A Methodological Study
http://www.cjmb.org Open Access Original Article Crescent Journal of Medical and Biological Sciences Vol. 5, No. 4, October 2018, 366 370 eissn 2148-9696 Iranian Version of Overactive Bladder Symptom Scale:
More informationVoiding Dysfunction. Hyo Serk Lee, Sae Woong Kim 1, Seung-June Oh 2, Myung-Soo Choo 3, Kyu-Sung Lee
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.3.178 Voiding Dysfunction Efficacy and Safety of Tamsulosin for Treating Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia:
More informationSubjective Measures of Efficacy: Quality of Life, Patient Satisfaction and Patient-Oriented Goals the Search for Value
european urology supplements 6 (2007) 438 443 available at www.sciencedirect.com journal homepage: www.europeanurology.com Subjective Measures of Efficacy: Quality of Life, Patient Satisfaction and Patient-Oriented
More informationVOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS
VOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS DR. FRANCIS LEE Voiding dysfunction Storage Emptying Common voiding dysfunction in elderly male Emptying BPH Storage Incontinence Overactive bladder Post-prostatectomy
More informationHiroshi Yagi, M.D., Gaku Arai, M.D., Shigehiro Soh, M.D., Hiroshi Okada, M.D.
Dokkyo Journal of Medical Sciences (1)(2017) (1):9 once-daily 15,2017 oxybutynin patch for overactive bladder in patients not tolerating oral antimuscarinic drugs 9 Efficacy and Safety of Once-daily Oxybutynin
More informationCase studies: LUTS. Case 1 history. Case 1 - questions. Case 1 - outcome. Case 2 - history. Case 1 learning point 14/07/2015 DR JON REES
Case 1 history Case studies: LUTS DR JON REES A 49 year old male comes to see you he has had gradual deterioration of his flow over the last few years- he saw a colleague of yours 6 weeks ago who recorded
More informationPredictors of short-term overactive bladder symptom improvement after transurethral resection of prostate in men with benign prostatic obstruction
bs_bs_banner International Journal of Urology (2014) 21, 1035 1040 doi: 10.1111/iju.12482 Original Article: Clinical Investigation Predictors of short-term overactive bladder symptom improvement after
More informationCurrent role of treatment in men with lower urinary tract symptoms combined with overactive bladder
Review Article Prostate Int 2014;2(2):43-49 P ROSTATE INTERNATIONAL Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder Seung Hwan Lee, Ji Youl Lee 1 Department
More informationLUTS after TURP: How come and how to manage? Matthias Oelke
LUTS after TURP: How come and how to manage? Matthias Oelke Department of Urology Global Congress on LUTD, Rome, 26 th June 2015 Disclosures Consultant, speaker, trial participant and/or research grants
More informationINJINTERNATIONAL. Sociodemographic Factors Related to Lower Urinary Tract Symptoms in Men: A Korean Community Health Survey.
Official Journal of Korean Continence Society / Korean Society of Urological Research / The Korean Children s Continence and Enuresis Society / The Korean Association of Urogenital Tract Infection and
More informationTamsulosin sustained release preparation in patients of lower urinary tract symptoms due to benign prostatic hyperplasia
J. Acad. Indus. Res. Vol. 1(11) April 2013 679 RESEARCH MANUSCRIPT ISSN: 2278-5213 Tamsulosin sustained release preparation in patients of lower urinary tract symptoms due to benign prostatic hyperplasia
More informationEfficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder
Urol Sci 21;21(1):38 43 ORIGINAL ARTICLE Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder Yih-Chou Chen, Chia-Yen Chen, Hann-Chorng
More informationRelationship between visual prostate score (VPSS) and maximum flow rate (Q max. ) in men with urinary tract symptoms
ORIGINAL ARTICLE Vol. 42 (2): 32-326, March - April, 206 doi: 0.590/S677-5538.IBJU.205.0032 Relationship between visual prostate score (VPSS) and maximum flow rate (Q max ) in men with urinary tract symptoms
More informationLong-term persistence with mirabegron in a real-world clinical setting
International Journal of Urology (2018) 25, 501--506 doi: 10.1111/iju.13558 Original Article: Clinical Investigation Long-term persistence with in a real-world clinical setting Naoki Wada, Masaki Watanabe,
More informationAdrenoceptor Antagonist Tamsulosin for the Treatment of Voiding Symptoms Improves Nocturia and Sleep Quality in Women. The α 1 FEMALE UROLOGY
The α 1 Adrenoceptor Antagonist Tamsulosin for the Treatment of Voiding Symptoms Improves Nocturia and Sleep Quality in Women Sun-Ouck Kim, Hyang Sik Choi, Dongdeuk Kwon FEMALE UROLOGY Department of Urology,
More informationLower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of
More informationPrevalence of Lower Urinary Tract Symptoms in Indigenous and Non-indigenous Women in Eastern Taiwan
Volume 109 Number 3 March 2010 Hepatitis C virus therapy Psychiatric morbidity in HIV-infected male prisoners Intravascular large B cell lymphoma in Taiwan Chinese incontinentia pigmenti NEMO gene mutations
More informationNOCTURIA WHAT S KEEPING YOU UP AT NIGHT? Frances Stewart RN,NCA
WHAT S KEEPING YOU UP AT NIGHT? Frances Stewart RN,NCA Objectives Be more knowledgeable in the diagnosis and treatment of nocturia Differentiate between urological causes of nocturia Select appropriate
More informationA unit of International Journal Foundation Page I 96
Occupational distribution of Patients with LUTS Single tertiary center experience. Part -4 (Medical Science) Chapter-III August/Vol.4.0/Issue-II ISSN NO : 2456-1045 ISSN CODE: 2456-1045 (Online) (ICV-MDS
More informationOriginal Article - Sexual Dysfunction
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.9.608 Original Article - Sexual Dysfunction http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.9.608&domain=pdf&date_stamp=2014-09-16
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationH6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)
H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,
More informationDrug Class Review on Overactive Bladder Drugs
Drug Class Review on Overactive Bladder Drugs Preliminary Scan Report #1 February 2014 Last Summary Review (June 2013) The Agency for Healthcare Research and Quality has not yet seen or approved this report
More information